AmoyDx of China will collaborate with AstraZeneca in developing a companion diagnostic for ovarian cancer with homologous recombination deficiency. Financial details of the agreement were not disclosed.
Groups to develop ovarian cancer companion diagnostic
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.